Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transformed Indolent Lymphoma”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Early research (Phase 1)Active Not RecruitingNCT03884998
What this trial is testing

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Lymphoma+4 more
City of Hope Medical Center 27
Testing effectiveness (Phase 2)WithdrawnNCT07030699
What this trial is testing

Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Testing effectiveness (Phase 2)Active Not RecruitingNCT05025800
What this trial is testing

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+17 more
M.D. Anderson Cancer Center 47
Early research (Phase 1)Not Yet RecruitingNCT07638982
What this trial is testing

Axatilimab + CAR-T for High-Risk Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)+3 more
Northside Hospital, Inc. 29
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Testing effectiveness (Phase 2)WithdrawnNCT02653989
What this trial is testing

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
Medivation, Inc.
Testing effectiveness (Phase 2)Study completedNCT03133221
What this trial is testing

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Who this might be right for
Non Hodgkin LymphomaFollicular LymphomaIndolent Lymphoma+6 more
University of Maryland, Baltimore 17
Testing effectiveness (Phase 2)Looking for participantsNCT06458439
What this trial is testing

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Testing effectiveness (Phase 2)UnknownNCT00397800
What this trial is testing

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Technical University of Munich 12
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Ended earlyNCT05328102
What this trial is testing

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large-cell B-cell Lymphoma
Xencor, Inc. 3
Early research (Phase 1)Active Not RecruitingNCT07166419
What this trial is testing

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Who this might be right for
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+12 more
Ohio State University Comprehensive Cancer Center
Early research (Phase 1)Study completedNCT05359211
What this trial is testing

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+6 more
Fred Hutchinson Cancer Center 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT03147885
What this trial is testing

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Extranodal Marginal Zone Lymphoma+12 more
Barbara Ann Karmanos Cancer Institute 43
Testing effectiveness (Phase 2)Study completedNCT02499003
What this trial is testing

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Johannes Gutenberg University Mainz 70
Next Page
24
24